RxDoctor Payments Data

Renee Minjarez, MD

Vascular Surgery · Bellevue, WANPI 1639373277

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,871 of the $5,869 with a category attached, or 66.0%. It is spread thinly across 23 manufacturers, the largest accounting for just 22.4%. 2025 is the largest year on record at $2,871, more than ten times the $242 reported in 2019.

$5,869in general payments, 2019–2025

Across 84 payments — averaging $69.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Silk Road Medical, Inc.$1K
  • Centinel Spine, LLC$1K
  • Endologix LLC$764
  • Medtronic$672
  • Inari Medical, Inc.$453
  • Shockwave Medical, Inc$447
  • plus $1K from 17 others
$48,232in research payments, 2019–2025

Across 4 payments — averaging $12,058 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bard Peripheral Vascular, Inc.$48K

What the payments were for

  • Travel & lodging$1,99734%
  • Food & beverage$3,87166%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,869 in reported general payments places this provider in the 55th percentile of 111 vascular surgery providers in Washington.

See all vascular surgery providers in Washington

Medicare billing

Part B allowed, 2024
$300,259
Medicare patients
432
Services billed
2,646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban167$181,581
EliquisApixaban70$78,275
Atorvastatin Calcium89$868
Cilostazol21$853
ClopidogrelClopidogrel Bisulfate48$404
Rosuvastatin Calcium48$324
Ezetimibe16$169
Triamcinolone Acetonide16$79
Cephalexin23$25
Warfarin Sodium11$12

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$75$181,581167 claims
PfizerEliquis$45$78,27570 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 111 vascular surgery providers in Washington.

Other vascular surgery in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →